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Purpose: To compare the hemostatic effect of sulfur hexafluoride 20% (SF6 20%) with 
lactated Ringer’s solution for prevention of early postoperative vitreous hemorrhage 
following diabetic vitrectomy.
Methods: In a prospective randomized clinical trial, 50 eyes undergoing diabetic 
vitrectomy were divided into two groups. At the conclusion of surgery, in one group 
the vitreous cavity was filled with SF6 20% while in the other group lactated Ringer’s 
solution was retained in the vitreous cavity. The two groups were compared for the 
rate of early postoperative vitreous hemorrhage.
Results: The incidence of vitreous hemorrhage was lower in the SF6 group than the 
Ringer’s group 4 days (20% vs 68%, P=0.001), 7 days (24% vs 60%, P=0.01) and 4 
weeks (16% vs 40%, P=0.059) after vitrectomy.
Conclusion: In comparison with lactated Ringer’s solution, SF6 20% had a significant 
hemostatic effect especially in the early postoperative period after diabetic vitrectomy 
and reduced the incidence of vitreous hemorrhage. 
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INTRODUCTION
Vitreous hemorrhage is one of the most serious 
complications of vitrectomy for proliferative 
diabetic retinopathy. The incidence of this 
complication ranges from 8% to 75%.1-6 It occurs 
most often in the early postoperative period 
and may be due to residual hemorrhage or 
bleeding from cut edges of fibrovascular tissue 
dissected during the operation. Advances in 
surgical technique and use of more sophisticated 
instrumentation including endodiathermy and 
endolaser have reduced the incidence of this 
condition to about 25%.7 
Postvitrectomy vitreous hemorrhage 
decreases visual acuity and impairs fundus 
visualization,  it  interferes  with  laser 
photocoagulation and detection of other 
retinal complications, furthermore it can 
predispose to cellular proliferation and may also 
increase intraocular pressure (IOP).8 Various 
substances including epsilon-aminocaproic 
acid,9 sodium hyaluronate,10,11 air,12 thrombin,13 
tranexamic acid,14,15 sulfur hexafluoride (SF6),16 
perfluoropropane (C3F8),17 and bevacizumab18,19 
have been used to prevent vitreous hemorrhage 
after diabetic vitrectomy.
Thompson et al20 used SF6 for tamponade 
of suspected retinal breaks or to prevent early 
postoperative vitreous hemorrhage. However, SF6 for Prevention of Postvitrectomy VH; Farrahi et al
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they did not report any data on the effect of the 
gas on the incidence of postoperative vitreous 
hemorrhage. Koutsandrea et al16 compared the 
hemostatic effect of SF6 20% versus balanced 
salt solution (BSS) in diabetic vitrectomy.
Regarding  the  lack  of  data  on  the 
incidence of vitreous hemorrhage following 
diabetic vitrectomy using lactated Ringer’s 
solution, this pilot study was performed to 
evaluate the hemostatic effect of SF6 20% as 
compared to lactated Ringer’s solution in the 
early postoperative period following diabetic 
vitrectomy. 
METHODS 
In a prospective randomized clinical trial, 67 eyes 
of 67 patients undergoing diabetic vitrectomy 
who met the inclusion criteria were randomly 
divided into two groups using a random 
number table. Informed consent was obtained 
from all patients preoperatively. Indications 
for vitrectomy were nonclearing vitreous 
hemorrhage and progressive fibrovascular 
proliferation unresponsive to panretinal laser 
photocoagulation. Patients with orthopedic or 
systemic problems who were unable to maintain 
prone position, monocular patients, subjects who 
were obliged to travel by air immediately after 
the operation, those who required concomitant 
cataract surgery, as well as patients with 
rubeosis iridis, extensive tractional retinal 
detachment with or without rhegmatogenous 
retinal detachment were excluded. Patients who 
required silicone oil injection intraoperatively 
were also excluded from the study. Seventeen 
eyes were excluded due to intraoperative use 
of silicone oil. Eventually 50 eyes of 50 patients 
fulfilled the inclusion and exclusion criteria of 
the study and were analyzed. 
All eyes underwent standard three port 
pars plana deep vitrectomy by two surgeons; 
complete posterior vitreous detachment was 
induced and delamination and segmentation of 
preretinal fibrovascular tissue was performed. 
We decided to use lactated Ringer’s solution 
instead of BSS during diabetic vitrectomy in 
both groups because BSS contains sodium 
citrate which has anticoagulant properties 
and may promote vitreous hemorrhage.21 The 
vitreous cavity was filled with SF6 20% in 25 
eyes but lactated Ringer’s solution was retained 
in the vitreous cavity of 25 other eyes at the 
end of the procedure. At the conclusion of 
surgery, the sclerotomies were repaired in the 
Ringer’s group but fluid was exchanged with 
SF6 20% in the SF6 group before repairing the 
sclerotomies. All patients in the SF6 group 
were instructed to maintain prone position for 
7 to 10 days after the operation. Patients were 
examined 1, 4 and 7 days as well as 4 weeks 
postoperatively. Follow-up was limited to 4 
weeks because SF6 completely clears from the 
eye and loses its tamponade effect by that time. 
Postoperative examinations included assessment 
of visual acuity, slitlamp biomicroscopy, IOP 
measurement and indirect ophthalmoscopy. 
The extent of vitreous hemorrhage was 
graded using indirect ophthalmoscopy according 
to the Diabetic Retinopathy Vitrectomy Study 
(DRVS) as follows:22 0, no vitreous hemorrhage; 
1, mild vitreous hemorrhage with visible fundus 
details; 2, moderate vitreous hemorrhage with no 
visible fundus details but with an orange fundus 
reflex; and 3, severe vitreous hemorrhage with 
no fundus details and no fundus reflex. Data 
analysis was performed using Chi-square test 
for frequency values and t-test for mean values; 
P values <0.05 were considered significant.
RESULTS 
Fifty eyes of 50 patients were enrolled and 
randomized to SF6 20% (25 eyes) versus lactated 
Ringer’s solution (25 eyes). Mean age was 
53.8±11.3 (range, 25-77) years in the SF6 group 
and 51.4±12.5 (range, 26-74) years in the Ringer’s 
group (P=0.417). Seventeen (68%) patients 
in the Ringer’s group and 13 (52%) patients 
in the SF6 group were female (P=0.248). The 
incidence of vitreous hemorrhage was higher 
in the Ringer’s group at all postoperative visits 
(Table 1). 
Eleven (22%) patients had systemic 
hypertension preoperatively and were receiving 
antihypertensive agents. The incidence of 
vitreous hemorrhage during the follow-up period 
was 54.5% (6 cases) among hypertensive patients SF6 for Prevention of Postvitrectomy VH; Farrahi et al
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and 43.5% (16 cases) among normotensive 
patients (P=0.425). Forty-two eyes were phakic 
of which 3 eyes (6%), including two eyes in the 
SF6 group and one eye in the Ringer’s group, 
developed cataracts postoperatively. Mean 
IOP was 12.13±1.24 mmHg in the SF6 group 
and 12.16±0.34 mmHg in the Ringer’s group 
(P=0.951) 4 weeks postoperatively. Forty-one 
(82%) patients had type II and 9 (18%) patients 
had type I diabetes mellitus. The incidence 
of vitreous hemorrhage during the follow-up 
period was 46.3% (19 cases) in type II diabetic 
patients and 44.4% (4 cases) in type I patients 
(P=0.87). 
Visual acuity was hand motions or worse 
in 26 (52%) patients and better than hand 
motions but less than 6/120 in 24 (48%) patients 
preoperatively with no significant difference 
between the two groups (data not presented). 
At final visit, 11 (22%) eyes had visual acuity 
worse than 6/120, including 7 (28%) eyes in 
the Ringer’s group and 4 (16%) eyes in the SF6 
group; 13 (26%) eyes had visual acuity between 
6/120 and 6/60, including 8 (32%) eyes in the 
Ringer’s group and 5 (20%) eyes in the SF6 
group; and 26 (52%) eyes had visual acuity 
better than 6/60, including 10 (40%) eyes in 
the Ringer’s group and 16 (64%) eyes in the 
SF6 group. The difference in postoperative 
visual acuity between the study groups was 
not statistically significant (P=0.235). 
DISCUSSION 
Despite laser treatment for proliferative diabetic 
retinopathy, the ocular sequelae of diabetes 
mellitus remain one of the most common 
indications for deep vitrectomy. Postoperative 
vitreous hemorrhage is a common complication 
of diabetic vitrectomy with a reported incidence 
of up to 75%. Advances in surgical technique 
and instrumentation including endodiathermy 
and endolaser photocoagulation have reduced 
the incidence of this complication to 25%.7 
Postoperative vitreous hemorrhage is associated 
with the following: (1) reduced vision which 
is annoying especially in monocular patients, 
(2) interference with fundus examination which 
may preclude diagnosis of postoperative problems 
such as retinal detachment, (3) interference 
with laser therapy, (4) ghost cell glaucoma, (5) 
introduction of platelet-derived growth factor 
(PDGF) and fibrinogen into the vitreous cavity 
causing fibrovascular proliferation, and (6) need 
for repeat surgery. 
Various substances have been used to 
prevent vitreous hemorrhage after diabetic 
vitrectomy. De Bustros et al9 used epsilon-
aminocaproic acid and found that it significantly 
reduced postoperative vitreous hemorrhage 
during the period of hospitalization, but its 
effect was not statistically significant later than 
2 weeks following the operation. Falk et al10 
and Packer et al11 used sodium hyaluronate in 
the vitreous cavity at the end of phakic diabetic 
vitrectomy which appeared to control vitreous 
hemorrhage in the immediate postoperative 
period but entails potential side effects such 
as elevated IOP. In a randomized study, 
Joondeph et al12 evaluated the hemostatic effect 
of air versus fluid in diabetic vitrectomy in 
an animal model and reported no statistically 
significant difference between them, which is 
in contrast to our study. This may be due to the 
short half-life and weak tamponade provided 
by air in the vitreous cavity. Laatikainen et 
al14 and Ramezani et al15 evaluated the effect 
of tranexamic acid in preventing vitreous 
hemorrhage after diabetic vitrectomy and 
reported no statistically significant effect.
Koutsandrea et al16 investigated the 
hemostatic effect of SF6 versus BSS in diabetic 
vitrectomy and reported no significant 
difference. The authors’ definition of vitreous 
hemorrhage was poor visualization of retinal 
Groups
Vitreous hemorrhage 
Mild Moderate Severe Total
4 days:  SF6 2 0 3 5 (20%)
  Ringer’s 4 7 6 11 (68%)
P value - - - 0.001
7 days:  SF6 3 0 3 6 (24%)
  Ringer’s 9 3 3 15 (60%)
P value - - - 0.01
4 weeks: SF6 1 1 2 4 (16%)
  Ringer’s 3 2 5 10 (40%)
P value - - - 0.059
Table 1. Incidence and severity of vitreous hemorrhage 
in the study groups during the follow-up periodSF6 for Prevention of Postvitrectomy VH; Farrahi et al
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vessels and fundus details and a red-orange 
or dark red fundus reflex, thereby they seem 
to have ignored mild vitreous hemorrhage.
Yang et al  17 evaluated the hemostatic 
effect of intravitreal injection of C3F8 10%, 
a long acting gas, on the occurrence of early 
postoperative vitreous hemorrhage in patients 
undergoing diabetic vitrectomy and concluded 
that it may be a useful adjunct to vitrectomy 
for proliferative diabetic retinopathy and 
may reduce the rate of recurrent vitreous 
hemorrhage in the early postoperative period 
(P=0.02). Ahmadieh et al18 and Modarres et 
al19 in separate studies evaluated intravitreal 
injection of bevacizumab before diabetic 
vitrectomy and both investigators concluded 
that this modality may decrease the incidence 
of early post-vitrectomy hemorrhage.
In our study, we employed lactated Ringer’s 
solution instead of BSS, because the latter contains 
citrate which can promote bleeding during and 
after surgery. Contrary to Koutsandrea et al,16 
we recorded all types of vitreous hemorrhage 
according to the DRVS study.22 The hemostatic 
effect of SF6 was significant during the first 
postoperative week, however this effect declined 
reaching borderline significance four weeks 
thereafter. However, we believe that this effect 
was clinically significant and had the sample size 
been larger, the observed difference would also 
have reached statistical significance at this time 
point. Further studies with larger sample size are 
needed to draw a definite conclusion. Diminution 
of the difference between the incidence of vitreous 
hemorrhage between the study groups at 28 days 
is probably due to elimination of SF6 from the eye 
after four weeks. The current report was a pilot 
study and despite our attempts to increase the 
number of cases, the absence of a predetermined 
sample size and the limited number of cases is a 
shortcoming. The surgeons were not masked to 
the intervention throughout the operation and 
this may be a source of bias.
It summary we may conclude that SF6 
20% in the vitreous cavity provides temporary 
tamponade and reduces the incidence of 
postoperative diabetic vitreous hemorrhage; 
disadvantages include the potential for inducing 
cataracts and prone positioning. 
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